Carnosinemia is a rare inherited metabolic disorder, caused by a deficiency in the enzyme carnosinase. Carnosinase is responsible for breaking down the dipeptide carnosine.¹ When this enzyme is absent or not functioning properly, carnosine accumulates in the brain and other tissues, leading to a range of symptoms. 

Although it is an extremely rare condition, carnosinemia² can have a huge impact on the nervous system. Neurological symptoms such as developmental delay, hypotonia and seizures often occur early in life and worsen over time. Understanding these symptoms is crucial for early diagnosis and management. 

Background on Carnosinemia

Carnosinemia is an inherited disorder resulting from mutations in the CNDP1 gene. This gene provides instructions for producing the enzyme carnosinase-1. This enzyme is normally found in the blood and is responsible for breaking down carnosine. In individuals with carnosinemia, the reduced activity of carnosinase leads to the accumulation of carnosine in bodily fluids and tissues. 

The condition follows an autosomal recessive inheritance pattern. This means that a child would have inherited two faulty copies of the CNDP1 gene (one from each parent) to develop the disorder. While carnosinemia is extremely rare, it is believed to be under-diagnosed due to its non-specific symptoms and lack of routine screening.

Although carnosine is not usually harmful, excessive accumulation in the central nervous system (CNS) appears to have toxic effects. These effects may interfere with brain development and neurotransmission, contributing to neurological symptoms. 

Pathophysiology

Without adequate carnosinase activity, carnosine accumulates in the blood, urine and other tissues, including the brain. This accumulation disrupts normal neurological development and function, although the exact mechanisms remain only partially understood. 

Carnosine is believed to have beneficial roles in the body under normal conditions. However, excess carnosine can have adverse effects in the CNS. One proposed mechanism is that high levels of carnosine alter neuronal excitability and disrupt neurotransmitter balance, potentially leading to seizures and other neurological symptoms. Additionally, carnosine accumulation may interfere with cellular energy metabolism or promote excitotoxicity, which can lead to cell damage or cell death.

Neurological Symptoms

The neurological symptoms of carnosinemia typically begin in infancy or early childhood. Symptoms can vary in severity. Developmental delay and seizures are the most commonly reported symptoms.

Developmental delay⁴ is often one of the earliest signs of carnosinemia. Affected infants may show delays in sitting, crawling, walking and speaking. Cognitive impairments can range from mild learning difficulties to profound intellectual disability. Language development is frequently affected, with children showing limited speech or difficulties in forming sentences. Motor skills may also be underdeveloped, contributing to coordination problems. 

Many children with carnosinemia exhibit hypotonia, or decreased muscle tone. This can affect posture and movement. As they grow, these children may have trouble with balance, walking or controlling movements. Some may also show signs of spasticity or abnormal reflexes. These motor symptoms often overlap with those seen in other neurodevelopmental disorders, making diagnosis more difficult. 

Seizures are another hallmark feature of carnosinemia and can appear in various forms, including focal or absence seizures. In some cases, seizures are frequent and resistant to standard antiepileptic medications. The presence of seizures significantly impacts quality of life and may contribute to further developmental delays.

Additional neurological symptoms may include irritability, excessive sleepiness, tremors and lethargy. In more severe cases, neurological deterioration may occur, potentially leading to loss of previously acquired skills. 

Diagnosis

As carnosinemia is extremely rare and presents with non-specific neurological symptoms, diagnosis can be challenging. Many of its symptoms overlap with more common neurological disorders, such as cerebral palsy, epilepsy and autism spectrum disorder. A thorough and systematic diagnostic approach is essential to accurately identify the condition.

The hallmark of carnosinemia is elevated levels of carnosine in the blood and urine. Measurement of carnosinase activity in blood plasma is crucial for confirming diagnosis. Affected individuals typically show very low or absent activity of carnosinase-1.

Management and Prognosis

Currently, there is no specific cure for carnosinemia. Treatment is focused on managing symptoms, supporting development and improving quality of life. As the condition is rare and not fully understood, care is tailored to each individual's needs. 

Antiepileptic drugs are commonly used to manage seizures. However, seizure control may be challenging in some cases, particularly when seizures are frequent or resistant to treatment.

Early intervention with physical therapy, occupational therapy and speech and language therapy can help children reach their developmental potential. These interventions may improve motor coordination and communication skills.

Although no specific diet has been proven to reduce carnosine levels, dietary adjustments may be recommended in some cases, particularly if there are feeding difficulties or growth concerns.

As carnosinemia is very rare, research focused on targeted treatments is limited. Some experimental approaches under consideration include enzyme replacement therapy³ and gene therapy. Greater awareness of the disorder and more reported cases are needed to encourage investment in research and clinical trials. 

The long-term outlook for individuals with carnosinemia varies widely. Some children have relatively stable symptoms with supportive care, while others may experience progressive neurological decline. Seizures and developmental disabilities often persist throughout life and in severe cases, individuals may remain dependent on caregivers for daily living.

Early diagnosis and comprehensive management can help improve quality of life, though the underlying neurological impairments are often lifelong. 

Conclusion

Carnosinemia is a rare but significant metabolic disorder with serious neurological consequences, particularly in early childhood. The condition arises from a deficiency in the enzyme carnosinase, leading to the accumulation of carnosine in the brain. This interferes with normal neural function and development, resulting in a spectrum of symptoms.

Currently, there is no treatment and management is largely symptomatic. A multidisciplinary approach remains essential in helping affected individuals and their families navigate the challenges posed by this complex condition.

Summary 

• Carnosinemia is a rare, autosomal recessive metabolic disorder caused by carnosinase-1 deficiency
• The condition leads to accumulation of carnosine in the brain, disrupting normal neurological function
• Key neurological symptoms include developmental delay, hypotonia, motor abnormalities and seizures
• Diagnosis involves biochemical testing (elevated carnosine, low enzyme activity) and confirmation through genetic testing of the CNDP1 gene
• There is no cure; treatment focuses on managing symptoms through therapies and antiepileptic medications
• Prognosis varies, but early diagnosis and supportive care can improve quality of life

Further research is needed to understand the disease mechanism and develop targeted therapies